

## 2024 ESMO Asia NEJ試験の発表

NEJ No.	Abstract Title	Presentation Number	Session Type	Speaker	Date
NEJ053C	A phase II study of nivolumab and ipilimumab combined with chemotherapy after lung stereotactic body radiotherapy as first-line therapy for stage IV non-small cell lung cancer	676P	Poster Display session	Kageaki Watanabe	Sat,07.12.2024
NEJ059	The Impact of Driver Gene Alteration Type on the Efficacy of Immune Checkpoint Inhibitors	645P	Poster Display session	Hajime Tsuruoka	Sat,07.12.2024